Neupane, N.; Bawek, S.; Gurusinghe, S.; Ghaffary, E.M.; Mirmosayyeb, O.; Thapa, S.; Falkson, C.; O’Regan, R.; Dhakal, A.
Oral SERD, a Novel Endocrine Therapy for Estrogen Receptor-Positive Breast Cancer. Cancers 2024, 16, 619.
https://doi.org/10.3390/cancers16030619
AMA Style
Neupane N, Bawek S, Gurusinghe S, Ghaffary EM, Mirmosayyeb O, Thapa S, Falkson C, O’Regan R, Dhakal A.
Oral SERD, a Novel Endocrine Therapy for Estrogen Receptor-Positive Breast Cancer. Cancers. 2024; 16(3):619.
https://doi.org/10.3390/cancers16030619
Chicago/Turabian Style
Neupane, Niraj, Sawyer Bawek, Sayuri Gurusinghe, Elham Moases Ghaffary, Omid Mirmosayyeb, Sangharsha Thapa, Carla Falkson, Ruth O’Regan, and Ajay Dhakal.
2024. "Oral SERD, a Novel Endocrine Therapy for Estrogen Receptor-Positive Breast Cancer" Cancers 16, no. 3: 619.
https://doi.org/10.3390/cancers16030619
APA Style
Neupane, N., Bawek, S., Gurusinghe, S., Ghaffary, E. M., Mirmosayyeb, O., Thapa, S., Falkson, C., O’Regan, R., & Dhakal, A.
(2024). Oral SERD, a Novel Endocrine Therapy for Estrogen Receptor-Positive Breast Cancer. Cancers, 16(3), 619.
https://doi.org/10.3390/cancers16030619
